Evidence map›Paper›PMID 38236824›Full record

ReviewPLOS digital health2024

Peer review of GPT-4 technical report and systems card.

Jack Gallifant, Amelia Fiske, Yulia A Levites Strekalova, Juan S Osorio-Valencia, Rachael Parke, Rogers Mwavu, Nicole Martinez, Judy Wawira Gichoya, Marzyeh Ghassemi, Dina Demner-Fushman and 3 more

Abstract readReview
In one paragraph

Review in PLOS digital health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Navigating the Prescription Drug Information System.Clinical pharmacology and therapeutics · 2026
    Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jack GallifantDepartment of Critical Care, Guy's & St Thomas' NHS Trust, London, United Kingdom.ORCID https://orcid.org/0000-0003-1306-2334
Amelia FiskeInstitute of History and Ethics in Medicine, Department of Clinical Medicine, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Yulia A Levites StrekalovaDepartment of Health Services Research, Management, and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, United States of America.
Juan S Osorio-ValenciaA.I. and Innovation Committee, Colombian Radiology Association, Medellin, Colombia.
Rachael ParkeCardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand.ORCID https://orcid.org/0000-0003-4209-0334
Rogers MwavuFaculty of Computing and Informatics, Mbarara University of Science and Technology, Mbarara, Uganda.
Nicole MartinezCenter for Biomedical Ethics, Stanford University, Stanford, California, United States of America.
Judy Wawira GichoyaDepartment of Radiology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Marzyeh GhassemiMassachusetts Institute of Technology, Electrical Engineering and Computer Science (EECS), Cambridge, Massachusetts, United States of America.
Dina Demner-FushmanNational Library of Medicine, NIH, HHS, Bethesda, Maryland, United States of America.
Liam G McCoyFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Leo Anthony CeliMassachusetts Institute of Technology, Laboratory for Computational Physiology, Cambridge, Massachusetts, United States of America.
Robin PierceThe Law School, Faculty of Humanities, Arts, and Social Sciences, University of Exeter, Exeter, United Kingdom.

Funding

Bridge2AI: Patient-Focused Collaborative Hospital Repository Uniting Standards (CHoRUS) for Equitable AIOT2OD032701 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI BIHORAC, AZRA, CLERMONT, GILLES · 2022 to 2025
$24.6M
Providing timely and effortless access to reliable health-related information for decision support and educationZIALM010019 · NLM · NATIONAL LIBRARY OF MEDICINE · PI DEMNER-FUSHMAN, DINA · 2021 to 2025
$12.0M
MUST Data Science Research Hub (MUDSReH) - Democratized Trusted Research Environment (dTRE)U54TW012043 · FIC · MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY · PI Leo Anthony G Celi, Jessica Elizabeth Haberer · 2021 to 2026
$6.9M
RADX TECH - CERES NANOSCIENCE INC NANOTRAP PARTICLE MANUFACTURING75N92020C00021 · NHLBI · CERES NANOSCIENCES, LLLP · PI DUNLAP, ROSS · 2021 to 2021
$4.0M
Critical Care Informatics: Ethical considerations around the use and sharing of health-related dataR01EB017205 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CELI, LEO ANTHONY G, MARK, ROGER GREENWOOD · 2014 to 2021
$3.8M
FIC NIH HHS U54 TW012043NHLBI NIH HHS 75N92020C00008NHLBI NIH HHS 75N92020C00021NIBIB NIH HHS R01 EB017205NIH HHS OT2 OD032701
6 · The paper itself

Abstract

The study provides a comprehensive review of OpenAI's Generative Pre-trained Transformer 4 (GPT-4) technical report, with an emphasis on applications in high-risk settings like healthcare. A diverse team, including experts in artificial intelligence (AI), natural language processing, public health, law, policy, social science, healthcare research, and bioethics, analyzed the report against established peer review guidelines. The GPT-4 report shows a significant commitment to transparent AI research, particularly in creating a systems card for risk assessment and mitigation. However, it reveals limitations such as restricted access to training data, inadequate confidence and uncertainty estimations, and concerns over privacy and intellectual property rights. Key strengths identified include the considerable time and economic investment in transparent AI research and the creation of a comprehensive systems card. On the other hand, the lack of clarity in training processes and data raises concerns about encoded biases and interests in GPT-4. The report also lacks confidence and uncertainty estimations, crucial in high-risk areas like healthcare, and fails to address potential privacy and intellectual property issues. Furthermore, this study emphasizes the need for diverse, global involvement in developing and evaluating large language models (LLMs) to ensure broad societal benefits and mitigate risks. The paper presents recommendations such as improving data transparency, developing accountability frameworks, establishing confidence standards for LLM outputs in high-risk settings, and enhancing industry research review processes. It concludes that while GPT-4's report is a step towards open discussions on LLMs, more extensive interdisciplinary reviews are essential for addressing bias, harm, and risk concerns, especially in high-risk domains. The review aims to expand the understanding of LLMs in general and highlights the need for new reflection forms on how LLMs are reviewed, the data required for effective evaluation, and addressing critical issues like bias and risk.

Identifiers

PMID38236824
PMCPMC10795998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.